ECOG STATISTICAL CENTER--DATA MANAGEMENT OFFICE

Summary

Principal Investigator: Robert Gray
Affiliation: Harvard University
Country: USA
Abstract: This office provides data management support for all ECOG studies, is responsible for registrations/randomizations, ADR reporting and reviews, and software development. The data Management Office at Frontier Science & Technology Research Foundation and the Statistical Office at the Dana Farber Cancer Institute together comprises the ECOG Statistical Center. The data management staff are involved in many aspects of ECOG activities and provide administrative and computing support for the Group.
Funding Period: 1994-08-05 - 2004-04-30
more information: NIH RePORT

Top Publications

  1. pmc Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
    Robert Dreicer
    Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 115:4090-5. 2009
  2. pmc Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92)
    Peter H Wiernik
    New York Medical College, Valhalla, NY, USA
    J Immunother 33:1006-9. 2010
  3. pmc A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Cancer 117:3374-82. 2011
  4. pmc Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group
    H H Yoon
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 68:863-70. 2011
  5. pmc Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
    Hugo F Fernandez
    Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 117:5306-13. 2011
  6. pmc Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA, USA
    J Clin Oncol 29:1709-14. 2011
  7. pmc Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292)
    A Bapsi Chakravarthy
    Department of Radiation Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, Preston Research Building, Room B 1003, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 81:e607-13. 2011
  8. pmc Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group
    Harry H Yoon
    Mayo Clinic, Rochester, MN 55905, USA
    BMC Cancer 11:176. 2011
  9. pmc Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer
    Glenn Liu
    University of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA
    Urol Oncol 31:211-8. 2013
  10. pmc Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
    Mitchell R Smith
    Fox Chase Cancer Center, Philadelphia, PA, USA
    Blood 118:3525-7. 2011

Detail Information

Publications153 found, 100 shown here

  1. pmc Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group
    Robert Dreicer
    Department of Solid Tumor Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio 44195, USA
    Cancer 115:4090-5. 2009
    ..A phase 2 trial of sorafenib was performed to determine the activity and toxicity of this agent in a multi-institutional setting in patients previously treated with 1 prior chemotherapy regimen...
  2. pmc Phase II study of interleukin-4 in indolent B-cell non-Hodgkin lymphoma and B-cell chronic lymphocytic leukemia: a study of the Eastern Cooperative Oncology Group (E5Y92)
    Peter H Wiernik
    New York Medical College, Valhalla, NY, USA
    J Immunother 33:1006-9. 2010
    ..8 months. Toxicity was generally mild with no grade 4 nonhematologic toxicity observed. Recombinant IL-4 treatment was well tolerated in this study but had minimal antitumor activity...
  3. pmc A phase 2 trial of bortezomib followed by the addition of doxorubicin at progression in patients with recurrent or metastatic adenoid cystic carcinoma of the head and neck: a trial of the Eastern Cooperative Oncology Group (E1303)
    Athanassios Argiris
    Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA
    Cancer 117:3374-82. 2011
    ..Bortezomib, an inhibitor of the 26S proteasome and NF-κB, may have antitumor activity in adenoid cystic carcinoma (ACC). Preclinical studies have shown synergy between bortezomib and doxorubicin...
  4. pmc Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group
    H H Yoon
    Division of Medical Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 68:863-70. 2011
    ....
  5. pmc Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin
    Hugo F Fernandez
    Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, Tampa, FL 33612, USA
    Blood 117:5306-13. 2011
    ..The addition of a single dose of GO in this setting did not improve outcomes...
  6. pmc Cetuximab for the treatment of advanced bronchioloalveolar carcinoma (BAC): an Eastern Cooperative Oncology Group phase II study (ECOG 1504)
    Suresh S Ramalingam
    Emory University, Winship Cancer Institute, Atlanta, GA, USA
    J Clin Oncol 29:1709-14. 2011
    ..We conducted a phase II study to evaluate cetuximab for the treatment of advanced BAC...
  7. pmc Long-term follow-up of a Phase II trial of high-dose radiation with concurrent 5-fluorouracil and cisplatin in patients with anal cancer (ECOG E4292)
    A Bapsi Chakravarthy
    Department of Radiation Oncology, Vanderbilt University Medical Center, 2220 Pierce Avenue, Preston Research Building, Room B 1003, Nashville, TN 37232, USA
    Int J Radiat Oncol Biol Phys 81:e607-13. 2011
    ..This Phase II clinical trial was performed to determine whether cisplatin could replace MMC in the treatment of anal cancer...
  8. pmc Genetic variation in DNA-repair pathways and response to radiochemotherapy in esophageal adenocarcinoma: a retrospective cohort study of the Eastern Cooperative Oncology Group
    Harry H Yoon
    Mayo Clinic, Rochester, MN 55905, USA
    BMC Cancer 11:176. 2011
    ..As a secondary aim, we investigated the rate of allelic imbalance between germline and tumor DNA...
  9. pmc Eastern Cooperative Oncology Group Phase II Trial of lapatinib in men with biochemically relapsed, androgen dependent prostate cancer
    Glenn Liu
    University of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA
    Urol Oncol 31:211-8. 2013
    ..This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer...
  10. pmc Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997
    Mitchell R Smith
    Fox Chase Cancer Center, Philadelphia, PA, USA
    Blood 118:3525-7. 2011
    ..Abnormalities involving chromosomes 5 or 7 were found in 10 cases, which suggests alkylator involvement. These data suggest that FC may induce more t-MN than fludarabine alone...
  11. pmc A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group
    K D Miller
    Department of Medicine, Division of Hematology and Oncology, Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, USA
    Ann Oncol 23:331-7. 2012
    ..E2104 was designed to evaluate the safety of two different strategies incorporating bevacizumab into anthracycline-containing adjuvant therapy as a precursor to a definitive randomized phase III trial...
  12. pmc Impact of high-risk classification by FISH: an eastern cooperative oncology group (ECOG) study E4A03
    Susanna J Jacobus
    Dana Farber Cancer Institute, Boston, MA, USA
    Br J Haematol 155:340-8. 2011
    ..FISH-based risk classification retained prognostic significance in patients receiving lenalidomide-based induction...
  13. pmc Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-term follow-up of an Eastern Cooperative Oncology Group study (E5493)
    Peter H Wiernik
    St Lukes Roosevelt Hospital Center, New York, NY, USA
    Leuk Lymphoma 53:1137-42. 2012
    ..Single agent topotecan has moderate activity for previously treated high-grade lymphoma equivalent to that of several newer agents, and should be considered for incorporation into multi-drug salvage chemotherapy programs...
  14. pmc Randomized phase III study of thoracic radiation in combination with paclitaxel and carboplatin with or without thalidomide in patients with stage III non-small-cell lung cancer: the ECOG 3598 study
    Tien Hoang
    Wisconsin Institute for Medical Research, 1111 Highland Ave, Madison, WI 53705, USA
    J Clin Oncol 30:616-22. 2012
    ..The primary objective of this study was to compare the survival of patients with unresectable stage III non-small-cell lung cancer (NSCLC) treated with combined chemoradiotherapy with or without thalidomide...
  15. ncbi Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501)
    Rathi N Pillai
    Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Cancer Chemother Pharmacol 74:177-83. 2014
    ..We conducted a phase II study to evaluate if modulation of Bcl-2 with 13-cis-retinoic acid (13-CRA) and interferon alpha could improve response rates when combined with paclitaxel in patients with recurrent SCLC...
  16. pmc Phase III study of radiation therapy with or without cis-platinum in patients with unresectable squamous or undifferentiated carcinoma of the head and neck: an intergroup trial of the Eastern Cooperative Oncology Group (E2382)
    Harry Quon
    Hospital of the University of Pennsylvania, 3400 Spruce Street 2 Donner, Philadelphia, PA 19104, USA
    Int J Radiat Oncol Biol Phys 81:719-25. 2011
    ....
  17. doi Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group
    Ruta D Rao
    Rush University Medical Center, 1725 W Harrison St, Suite 809, Chicago, IL 60612, USA
    Med Oncol 28:S39-47. 2011
    ..This trial provides important toxicity information about fenretinide, a retinoid that has been used in the prevention setting, because it is the only placebo-controlled, double-blind randomized study ever performed...
  18. pmc Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
    Peter L Greenberg
    Stanford University Cancer Center, CA 94305, USA
    Blood 114:2393-400. 2009
    ..In comparison with SC alone, patients receiving EPO with or without granulocyte colony-stimulating factor plus SC had improved erythroid responses, similar survival, and incidence of acute myeloid leukemia transformation...
  19. pmc Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group
    Elizabeth Poplin
    Cancer Institute of New Jersey, 195 Little Albany St, New Brunswick, NJ 08903, USA
    J Clin Oncol 27:3778-85. 2009
    ..E6201 was designed to compare overall survival (OS) of standard weekly GEM 1,000 mg/m(2)/30 minutes versus GEM FDR 1,500 mg/m(2)/150 minutes or GEM 1,000 mg/m(2)/100 minutes/day 1 plus oxaliplatin 100 mg/m(2)/day 2 every 14 days (GEMOX)...
  20. pmc Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial
    Morie A Gertz
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 147:677-80. 2009
    ..Future studies of Waldenström macroglobulinaemia should report minor responses because they are associated with clinically meaningful benefits. This trial was registered at http://www.clinicaltrials.gov as #NCT00005609...
  21. pmc Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study
    Sandra J Horning
    Department of Medicine, Stanford University, CA, USA
    Blood 115:775-7; quiz 918. 2010
    ..This trial was registered at www.clinicaltrials.gov as #NCT00274924 [corrected]...
  22. pmc Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501
    Leora Horn
    Vanderbilt University, Nashville, TN, USA
    J Clin Oncol 27:6006-11. 2009
    ..To investigate the efficacy and safety of bevacizumab plus cisplatin and etoposide in patients with extensive-stage disease, small-cell lung cancer (ED-SCLC)...
  23. pmc Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial
    S Vincent Rajkumar
    Mayo Clinic, Rochester, Minnesota, USA
    Lancet Oncol 11:29-37. 2010
    ..High-dose dexamethasone is a mainstay of therapy for multiple myeloma. We studied whether low-dose dexamethasone in combination with lenalidomide is non-inferior to and has lower toxicity than high-dose dexamethasone plus lenalidomide...
  24. pmc Phase II trial of pegylated liposomal doxorubicin plus docetaxel with and without trastuzumab in metastatic breast cancer: Eastern Cooperative Oncology Group trial E3198
    Antonio C Wolff
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Breast Cancer Res Treat 121:111-20. 2010
    ..In conclusion, concurrent administration of trastuzumab with PLD-docetaxel was not associated with higher risk of cardiac toxicity compared with PLD-docetaxel alone, but led to excessive hand-foot syndrome...
  25. pmc Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494
    Jane N Winter
    Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA
    Clin Cancer Res 16:2435-42. 2010
    ..S. Intergroup trial comparing conventional cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy to rituximab-CHOP (R-CHOP) induction, with or without maintenance rituximab...
  26. pmc Epidermal growth factor receptor, C-kit, and Her2/neu immunostaining in advanced or recurrent thymic epithelial neoplasms staged according to the 2004 World Health Organization in patients treated with octreotide and prednisone: an Eastern Cooperative Onc
    Seena C Aisner
    Department of Pathology, UMDNJ NJMS, Newark, New Jersey, USA
    J Thorac Oncol 5:885-92. 2010
    ..Three markers, EGFR, C-kit, and Her2/neu, were selected for evaluation in patients with advanced thymic epithelial tumors treated on E1C97...
  27. pmc Phase II study of sorafenib in combination with docetaxel and cisplatin in the treatment of metastatic or advanced gastric and gastroesophageal junction adenocarcinoma: ECOG 5203
    Weijing Sun
    Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Clin Oncol 28:2947-51. 2010
    ..A phase II study was conducted to determine the efficacy and toxicity of combined sorafenib, docetaxel, and cisplatin in patients with metastatic or advanced adenocarcinoma of stomach or gastroesophageal junction (GEJ)...
  28. pmc Adult patients with acute myeloid leukemia who achieve complete remission after 1 or 2 cycles of induction have a similar prognosis: a report on 1980 patients registered to 6 studies conducted by the Eastern Cooperative Oncology Group
    Jacob M Rowe
    Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center and Technion, Israel Institute of Technology, Haifa, Israel
    Cancer 116:5012-21. 2010
    ....
  29. doi Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer
    Alan Sandler
    Division of Hematology Oncology, Department of Medicine, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Portland, OR 97239 3098, USA
    J Thorac Oncol 5:1416-23. 2010
    ..An analysis of survival and safety outcomes based on histology is presented here...
  30. pmc Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognostic in
    Ranjana H Advani
    Stanford University, Stanford, CA 94305, USA
    Br J Haematol 151:143-51. 2010
    ..The prognostic discrimination provided by the E-IPI for low and low-intermediate elderly DLBCL patients needs validation by other datasets...
  31. pmc Does microgranular variant morphology of acute promyelocytic leukemia independently predict a less favorable outcome compared with classical M3 APL? A joint study of the North American Intergroup and the PETHEMA Group
    Martin S Tallman
    Memorial Sloan Kettering Cancer Center, Department of Medicine, New York, NY, USA
    Blood 116:5650-9. 2010
    ..07), and 15% (P = .005), respectively. When outcomes were adjusted for the white blood cell count or the relapse risk score, none of these outcomes were significantly different between patients with M3V and classical M3 APL...
  32. pmc A randomized trial of combination anastrozole plus gefitinib and of combination fulvestrant plus gefitinib in the treatment of postmenopausal women with hormone receptor positive metastatic breast cancer
    Robert W Carlson
    Eastern Cooperative Oncology Group, Boston, MA, USA
    Breast Cancer Res Treat 133:1049-56. 2012
    ..Further studies of EGFR inhibition plus endocrine therapy do not appear warranted, but if performed should include attempts to identify biomarkers predictive of antitumor activity...
  33. pmc Prognostic implications of additional chromosome abnormalities among patients with de novo acute promyelocytic leukemia with t(15;17)
    Peter H Wiernik
    Continuum Cancer Centers of New York at St Lukes, Roosevelt and Beth Israel Medical Centers, Roosevelt Hospital Center, Ste 11C 02, 1000 10th Ave, New York, NY 10019, USA
    Med Oncol 29:2095-101. 2012
    ..Patients with APL and t(15;17) alone are significantly more sensitive to treatment with ATRA than are patients with t(15;17) and additional cytogenetic abnormalities...
  34. pmc Phase II 2-arm trial of the proteasome inhibitor, PS-341 (bortezomib) in combination with irinotecan or PS-341 alone followed by the addition of irinotecan at time of progression in patients with locally recurrent or metastatic squamous cell carcinoma of
    Jill Gilbert
    Vanderbilt University Medical Center, Nashville, Tennessee 37232, USA
    Head Neck 35:942-8. 2013
    ..Irinotecan demonstrates single-agent activity in head and neck cancer but activates NF-κB, promoting cell survival and resistance. Bortezomib is a proteasome inhibitor that inactivates NF-κB...
  35. doi All-trans retinoic acid and late relapses in acute promyelocytic leukemia: very long-term follow-up of the North American Intergroup Study I0129
    Dan Douer
    Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, USA
    Leuk Res 37:795-801. 2013
    ..Nine (4.6%) relapsed late (>3 years from CR), the last occurred after 4.6 years; 7 of them were still alive after 5.5-15 years. In APL patients, late relapses are uncommon, and those who sustain CR >5 years can be considered cured...
  36. doi Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594
    Tien Hoang
    Hematology Oncology Section, University of Wisconsin, Wisconsin Institutes for Medical Research, Madison, WI 53705, USA
    Lung Cancer 81:47-52. 2013
    ..We conducted this analysis to determine whether survival of advanced NSCLC patients treated with platin-based chemotherapy doublets involving paclitaxel, docetaxel or gemcitabine was dependent on histological subtypes and treatment regimen...
  37. pmc A multigene expression assay to predict local recurrence risk for ductal carcinoma in situ of the breast
    Lawrence J Solin
    Department of Radiation Oncology, Albert Einstein Medical Center, Philadelphia, PA 19141, USA
    J Natl Cancer Inst 105:701-10. 2013
    ....
  38. pmc A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602)
    Craig L Slingluff
    Department of Surgery, Human Immune Therapy Center, University of Virginia, Charlottesville, Virginia, USA
    Clin Cancer Res 19:4228-38. 2013
    ..This multicenter randomized trial was designed to evaluate whether melanoma helper peptides augment cytotoxic T lymphocyte (CTL) responses to a melanoma vaccine and improve clinical outcome in patients with advanced melanoma...
  39. pmc Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404)
    Kristen Ganjoo
    Stanford University, Stanford, CA, USA
    Leuk Lymphoma 55:768-72. 2014
    ..Studies of novel therapeutics are needed for this patient population, whose clinical outcome remains poor...
  40. pmc A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404)
    Daniel R Greenwald
    Stanford University, Stanford, CA, USA
    J Hematol Oncol 6:46. 2013
    ..Median overall survival (OS) was 9 months (90% CI, 5 - 16 months). Although sorafenib has demonstrated activity in solid malignancies it demonstrated low single agent activity in treatment of DLBCL. ..
  41. pmc Body mass index and its association with clinical outcomes for advanced non-small-cell lung cancer patients enrolled on Eastern Cooperative Oncology Group clinical trials
    Suzanne E Dahlberg
    Department of Biostatistics and Computational Biology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Thorac Oncol 8:1121-7. 2013
    ..Obesity increases the risk of death from many adverse health outcomes and has also been linked with cancer outcomes. The impact of obesity on outcomes of advanced non-small-cell lung cancer patients is unclear...
  42. pmc Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes
    Sebastien Malinge
    Division of Hematology Oncology, Northwestern University, Chicago, IL
    Blood 122:e33-43. 2013
    ..These findings indicate that the final epigenetic landscape of DS-AMKL is the result of sequential and opposing changes in DNA methylation occurring at specific times in the disease development. ..
  43. pmc ECOG phase II trial of graded-dose peginterferon α-2b in patients with metastatic melanoma overexpressing basic fibroblast growth factor (E2602)
    Ronald S Go
    Authors Affiliations Gundersen Health System Gundersen Medical Foundation, La Crosse, Wisconsin Dana Farber Cancer Institute, Boston, Massachusetts University of Alabama Comprehensive Cancer Center, Birmingham, Alabama and University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania
    Clin Cancer Res 19:6597-604. 2013
    ..The primary objective was suppression of plasma FGF-2 to within reference range (≤ 7.5 pg/mL)...
  44. pmc Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503)
    J R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States Electronic address
    Eur J Cancer 50:302-8. 2014
    ....
  45. doi E5501: phase II study of topotecan sequenced with etoposide/cisplatin, and irinotecan/cisplatin sequenced with etoposide for extensive-stage small-cell lung cancer
    Taofeek K Owonikoko
    Emory University, Atlanta, GA, USA
    Cancer Chemother Pharmacol 73:171-80. 2014
    ..Sequence-dependent improved efficacy of topoisomerase I followed by topoisomerase 2 inhibitors was assessed in a randomized phase II study in extensive-stage small-cell lung cancer (SCLC)...
  46. pmc Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution
    Janice P Dutcher
    1 Department of Oncology, Montefiore Medical Center, Bronx, New York
    J Interferon Cytokine Res 34:376-84. 2014
    ..Therapeutic interventions in the role of IL-1 in inflammatory conditions and cancer may be further informed by our definition of its clinical and biological effects in this evaluation of dose and schedule...
  47. pmc A four-marker signature of TNF-RII, TGF-α, TIMP-1 and CRP is prognostic of worse survival in high-risk surgically resected melanoma
    Ahmad A Tarhini
    University of Pittsburgh Cancer Institute, UPMC Cancer Pavilion, 5150 Centre Avenue, 5th Floor, Suite 555, Pittsburgh, PA 15232, USA
    J Transl Med 12:19. 2014
    ..E1694 tested GM2-KLH-QS21 vaccine versus high-dose interferon-α2b (HDI) as adjuvant therapy for operable stage IIB-III melanoma. We tested banked serum specimens from patients in the vaccine arm of E1694 for prognostic biomarkers...
  48. ncbi Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103
    Kathryn J Ruddy
    Mayo Clinic, Rochester, MN, USA
    Breast Cancer Res Treat 144:591-7. 2014
    ..Pre-chemotherapy AMH level is a potential novel biomarker for CRA in premenopausal women with early stage breast cancer. Further research to evaluate the clinical utility of AMH testing is warranted...
  49. pmc Phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic head and neck cancer: an eastern cooperative oncology group trial
    Athanassios Argiris
    Division of Hematology Oncology, University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center, 7979 Wurzbach Rd, MC8232, Zeller Building, 4th Floor, Room Z418, San Antonio, TX 78229, USA
    J Clin Oncol 31:1405-14. 2013
    ..We hypothesized that the addition of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, to docetaxel would enhance therapeutic efficacy in squamous cell carcinoma of the head and neck (SCCHN)...
  50. pmc Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial
    Jennifer A Kanakry
    Johns Hopkins University, School of Medicine, Baltimore, MD 21287, USA
    Blood 121:3547-53. 2013
    ..These results confirm that plasma EBV-DNA is highly concordant with EBER-ISH in HL and suggest that it may have prognostic utility both at baseline and after therapy. This trial was registered at www.clinicaltrials.gov as #NCT00003389...
  51. pmc Prognostic models to predict survival in non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin with or without bevacizumab
    Tien Hoang
    Department of Medicine, University of Wisconsin, Madison, Wisconsin 53705, USA
    J Thorac Oncol 7:1361-8. 2012
    ....
  52. pmc Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499
    Mitchell R Smith
    Lymphoma Service, Fox Chase Cancer Center, Room C307, 333 Cottman Ave, Philadelphia, PA 19111, USA
    J Clin Oncol 30:3119-26. 2012
    ....
  53. pmc Neuropathy is not associated with clinical outcomes in patients receiving adjuvant taxane-containing therapy for operable breast cancer
    Bryan P Schneider
    Eastern Cooperative Oncology Group, 535 Barnhill Dr, Indiana Cancer Pavilion, Indianapolis, IN 46202, USA
    J Clin Oncol 30:3051-7. 2012
    ..Therefore, we sought to determine whether neuropathy was associated with breast cancer recurrence in a clinical trial population who received adjuvant taxane therapy...
  54. pmc Obesity at diagnosis is associated with inferior outcomes in hormone receptor-positive operable breast cancer
    Joseph A Sparano
    Albert Einstein College of Medicine, Montefiore Medical Center, Bronx, New York, USA
    Cancer 118:5937-46. 2012
    ..Obesity has been associated with inferior outcomes in operable breast cancer, but the relation between body mass index (BMI) and outcomes by breast cancer subtype has not been previously evaluated...
  55. pmc Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial
    King L Tan
    Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, Canada
    Blood 120:3280-7. 2012
    ..We demonstrate the prognostic significance of TAMs in locally extensive and advanced-stage CHL in a multicenter phase 3 randomized controlled clinical trial...
  56. pmc A double-blind randomized discontinuation phase-II study of sorafenib (BAY 43-9006) in previously treated non-small-cell lung cancer patients: eastern cooperative oncology group study E2501
    Heather A Wakelee
    Department of Medicine, Division of Oncology, Stanford Cancer Institute, Stanford University, Stanford, CA, USA
    J Thorac Oncol 7:1574-82. 2012
    ..Sorafenib is a raf kinase and angiogenesis inhibitor with activity in multiple cancers. This phase-II study in heavily pretreated non-small-cell lung cancer (NSCLC) patients (≥ 2 prior therapies) used a randomized discontinuation design...
  57. pmc Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years
    Amye J Tevaarwerk
    Medical Oncology Clinic, University of Wisconsin Carbone Comprehensive Cancer Center, Madison, Wisconsin 53705 2275, USA
    Cancer 119:1140-8. 2013
    ..The objective of the current study was to determine whether survival improved for patients who developed distant recurrence of breast cancer after receiving adjuvant therapy...
  58. pmc Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab
    David O Bates
    Microvascular Research Laboratories, Department of Physiology and Pharmacology, University of Bristol, Bristol, United Kingdom
    Clin Cancer Res 18:6384-91. 2012
    ..We tested the hypothesis that prolonged progression-free survival (PFS) would occur only in patients with low relative VEGF(165)b levels treated with bevacizumab...
  59. pmc Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma
    David W Scott
    Centre for Lymphoid Cancer, BC Cancer Agency, Vancouver, British Columbia, Canada
    J Clin Oncol 31:692-700. 2013
    ....
  60. pmc Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)
    Leo I Gordon
    Northwestern University Feinberg School of Medicine and Robert H Lurie Comprehensive Cancer Center, Chicago, IL, USA
    J Clin Oncol 31:684-91. 2013
    ..Our aim was to determine if failure-free survival was superior in patients treated with the Stanford V regimen compared with ABVD...
  61. pmc Phase 2 study of preoperative radiation with concurrent capecitabine, oxaliplatin, and bevacizumab followed by surgery and postoperative 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX), and bevacizumab in patients with locally advanced rectal cancer: ECO
    Jerome C Landry
    Emory University and Winship Cancer Institute, Atlanta, Georgia, USA
    Cancer 119:1521-7. 2013
    ....
  62. pmc Phase II Trial of Paclitaxel/Cisplatin Followed by Surgery and Adjuvant Radiation Therapy and 5-Fluorouracil/Leucovorin for Gastric Cancer (ECOG E7296)
    A Bapsi Chakravarthy
    Vanderbilt Ingram Cancer Center Nashville, TN
    Gastrointest Cancer Res 5:191-7. 2012
    ..It was hypothesized that combining induction chemotherapy with postoperative chemoradiation would be well tolerated and improve pathologic complete response...
  63. pmc Prognostic and predictive value of tumor vascular endothelial growth factor gene amplification in metastatic breast cancer treated with paclitaxel with and without bevacizumab; results from ECOG 2100 trial
    Bryan P Schneider
    Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana 46202, USA
    Clin Cancer Res 19:1281-9. 2013
    ..We have previously reported associations between candidate VEGFA single-nucleotide polymorphisms (SNP) and overall survival (OS) in E2100. The associations between tumor VEGFA amplification and outcome are evaluated here...
  64. pmc The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496
    Andrew M Evens
    The University of Massachusetts Medical School, Worcester, MA 01655, USA
    Br J Haematol 161:76-86. 2013
    ..9%, respectively, P < 0·0001). Altogether, the marked HL age-dependent survival differences appeared attributable primarily to non-HL events...
  65. pmc Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenib
    Melissa A Wilson
    Authors Affiliations Hematology Oncology, Department of Medicine, University of Pennsylvania Translational Medicine and Human Genetics, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania Abramson Cancer Center of the University of Pennsylvania, Philadelphia University of Pittsburgh School of Medicine, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania Dana Farber Cancer Institute Massachusetts General Hospital Cancer Center, Massachusetts General Hospital, Boston, Massachusetts Department of Pathology, Yale University School of Medicine and Section of Medical Oncology, Yale Cancer Center, New Haven, Connecticut
    Clin Cancer Res 20:3328-37. 2014
    ..We assessed the association of somatic mutations with clinicopathologic features and clinical outcomes in patients with metastatic melanoma treated on E2603, comparing treatment with carboplatin, paclitaxel ± sorafenib (CP vs...
  66. doi Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer
    Angela DeMichele
    Department of Medicine Hematology Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
    Cancer Res 69:4184-91. 2009
    ..Kaplan-Meier plots show that all patients in this group relapsed by 24 months from diagnosis. This poor-risk haplotype was quite common overall (estimated frequency, 0.20) and twice as frequent among Blacks (estimated frequency, 0.41)...
  67. pmc Phase I study of adenovirus p53 administered by bronchoalveolar lavage in patients with bronchioloalveolar cell lung carcinoma: ECOG 6597
    Vicki Keedy
    Vanderbilt Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA
    J Clin Oncol 26:4166-71. 2008
    ..This pilot phase I trial evaluated the safety and maximum-tolerated dose of p53 gene transfer using an adenovirus vector (Ad-p53) delivered via bronchoalveolar lavage (BAL) to patients with bronchioloalveolar lung carcinoma (BAC)...
  68. pmc Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 459
    Julie R Brahmer
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    J Thorac Oncol 6:103-8. 2011
    ..Bevacizumab improved overall survival. However, an unplanned subset analysis did not show a survival benefit for females treated with bevacizumab...
  69. ncbi Phase III study of standard combination versus rotating regimen of induction chemotherapy in patients with hormone insensitive metastatic breast cancer: an Eastern Cooperative Oncology Group Intergroup Study (E3185)
    Kishan J Pandya
    University of Rochester, James P Wilmot Cancer Center, Rochester, New York 14642, USA
    Am J Clin Oncol 30:113-25. 2007
    ....
  70. ncbi Induction of adaptive Anti-HER2/neu immune responses in a Phase 1B/2 trial of 2B1 bispecific murine monoclonal antibody in metastatic breast cancer (E3194): a trial coordinated by the Eastern Cooperative Oncology Group
    Hossein Borghaei
    Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    J Immunother 30:455-67. 2007
    ....
  71. pmc The clinical characteristics, therapy and outcome of 85 adults with acute lymphoblastic leukemia and t(4;11)(q21;q23)/MLL-AFF1 prospectively treated in the UKALLXII/ECOG2993 trial
    David I Marks
    Adult BMT Unit, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
    Haematologica 98:945-52. 2013
    ..Prospective trials are required to determine whether poor outcomes in older patients can be improved by reduced-intensity conditioning allografts. NCT00002514 www.clinicaltrials.gov...
  72. pmc A phase I-II study of combined blockade of the ErbB receptor network with trastuzumab and gefitinib in patients with HER2 (ErbB2)-overexpressing metastatic breast cancer
    Carlos L Arteaga
    Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University, 2200 Pierce Avenue, Nashville, TN 37232, USA
    Clin Cancer Res 14:6277-83. 2008
    ..To determine the safety, and efficacy of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in combination with trastuzumab in patients with metastatic HER2-positive metastatic breast cancer...
  73. pmc A phase II study of paclitaxel + etoposide + cisplatin + concurrent radiation therapy for previously untreated limited stage small cell lung cancer (E2596): a trial of the Eastern Cooperative Oncology Group
    Leora Horn
    Department of Hematology Oncology, Vanderbilt University, Nashville, Tennessee, USA
    J Thorac Oncol 4:527-33. 2009
    ....
  74. pmc Predicting gene promoter methylation in non-small-cell lung cancer by evaluating sputum and serum
    S A Belinsky
    Lung Cancer Program, Lovelace Respiratory Research Institute, 2425 Ridgecrest Dr SE, Albuquerque, NM 87108, USA
    Br J Cancer 96:1278-83. 2007
    ..These studies demonstrate that sputum can be used effectively as a surrogate for tumour tissue to predict the methylation status of advanced lung cancer where biopsy is not feasible...
  75. ncbi A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): a trial of the Eastern Cooperative Oncology Group
    Robert W Carlson
    Stanford University, Stanford, California 94305 5826, USA
    Cancer Invest 24:677-81. 2006
    ..To assess the activity and toxicity of valspodar (PSC-833) in combination with paclitaxel in women with anthracycline refractory, metastatic breast cancer...
  76. pmc Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
    David C Johnson
    Section of Haemato oncology, Institute of Cancer Research, London, United Kingdom
    Blood 112:4924-34. 2008
    ..The clinical trials described in this paper have been registered as follows: MRC Myeloma IX: ISRCTN68454111; Hovon-50: NCT00028886; and ECOG EA100: NCT00033332...
  77. pmc Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999
    Larry D Cripe
    Indiana University Simon Cancer Center, Indianapolis, IN, USA
    Blood 116:4077-85. 2010
    ..We conclude that zosuquidar did not improve outcome in older acute myeloid leukemia, in part, because of the presence P-gp independent mechanisms of resistance. This trial is registered at www.clinicaltrials.gov as #NCT00046930...
  78. pmc Pilot study evaluating the interaction between paclitaxel and protease inhibitors in patients with human immunodeficiency virus-associated Kaposi's sarcoma: an Eastern Cooperative Oncology Group (ECOG) and AIDS Malignancy Consortium (AMC) trial
    Mary Cianfrocca
    Feinberg School of Medicine, Northwestern University, Chicago, IL, USA
    Cancer Chemother Pharmacol 68:827-33. 2011
    ..Protease inhibitors are commonly used to treat HIV infection and are known to inhibit cytochrome P450. We sought to determine whether protease inhibitors alter the pharmacokinetics of paclitaxel...
  79. pmc Phase II trial of weekly ixabepilone in men with metastatic castrate-resistant prostate cancer (E3803): a trial of the Eastern Cooperative Oncology Group
    Glenn Liu
    University of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA
    Clin Genitourin Cancer 10:99-105. 2012
    ..Here we evaluate the activity of a weekly ixabepilone in men with metastatic castrate-resistant prostate cancer to minimize hematologic toxicity...
  80. pmc Impact of gene expression profiling-based risk stratification in patients with myeloma receiving initial therapy with lenalidomide and dexamethasone
    Shaji K Kumar
    Division of Hematology, Mayo Clinic Rochester, Rochester, MN 55905, USA
    Blood 118:4359-62. 2011
    ..74, 0.7, and 0.7, respectively. Here we demonstrate the prognostic value for GEP risk stratification in a group of patients primarily treated with novel agents. This trial was registered at www.clinicaltrials.gov as #NCT00098475...
  81. pmc Relationship between quantitative GRB7 RNA expression and recurrence after adjuvant anthracycline chemotherapy in triple-negative breast cancer
    Joseph A Sparano
    Albert Einstein College of Medicine, Bronx, New York 10461, USA
    Clin Cancer Res 17:7194-203. 2011
    ..To conduct an exploratory analysis of the relationship between gene expression and recurrence in patients with operable triple-negative breast cancer (TNBC) treated with adjuvant doxorubicin-containing chemotherapy...
  82. pmc Differential effect of age on survival in advanced NSCLC in women versus men: analysis of recent Eastern Cooperative Oncology Group (ECOG) studies, with and without bevacizumab
    H A Wakelee
    Department of Medicine Division of Oncology, Stanford University, Stanford, CA, USA
    Lung Cancer 76:410-5. 2012
    ..The impact of age on prognosis in advanced stage non-small cell lung cancer (NSCLC) may differ by sex...
  83. doi A phase II trial of capecitabine in combination with the farnesyltransferase inhibitor tipifarnib in patients with anthracycline-treated and taxane-resistant metastatic breast cancer: an Eastern Cooperative Oncology Group Study (E1103)
    Tianhong Li
    Montefiore Medical Center, Albert Einstein Cancer Center, Bronx, NY, USA
    Breast Cancer Res Treat 134:345-52. 2012
    ..The tipifarnib-capecitabine combination is not more effective than capecitabine alone in MBC patients who were previously treated with an anthracycline and taxane therapy...
  84. pmc Prognostic value of biologic subtype and the 21-gene recurrence score relative to local recurrence after breast conservation treatment with radiation for early stage breast carcinoma: results from the Eastern Cooperative Oncology Group E2197 study
    Lawrence J Solin
    Department of Radiation Oncology, Albert Einstein Medical Center, 5501 Old York Road, Philadelphia, PA 19141, USA
    Breast Cancer Res Treat 134:683-92. 2012
    ..03). The 10-year rates of local recurrence and local-regional recurrence were reasonably low in all subsets of patients. Neither biologic subtype nor 21-gene recurrence score should preclude breast conservation treatment with radiation...
  85. pmc Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy
    Mary Cianfrocca
    Department of Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Cancer 116:3969-77. 2010
    ..A randomized trial comparing the efficacy and toxicity of paclitaxel and PLD was performed, and the effects of therapy on symptom palliation and quality of life were determined...
  86. pmc Relationship between elevated immunoglobulin free light chain and the presence of IgH translocations in multiple myeloma
    S Kumar
    Division of Hematology, Mayo Clinic, Rochester, MN 55905, USA
    Leukemia 24:1498-505. 2010
    ..A system including both these risk factors allows better prediction of outcome...
  87. pmc Survival-adjusted health-related quality of life (HRQL) among patients with metastatic breast cancer receiving paclitaxel plus bevacizumab versus paclitaxel alone: results from Eastern Cooperative Oncology Group Study 2100 (E2100)
    David Cella
    Department of Medical Social Sciences, Northwestern University Feinberg Medical School, 625 N Michigan Avenue, Suite 2700, Chicago, IL 60611, USA
    Breast Cancer Res Treat 130:855-61. 2011
    ..The addition of bevacizumab was not associated with additional side effect burden from the patient perspective and was associated with a greater reduction in breast cancer-specific concerns. No other differences were noted...
  88. pmc Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group
    Mark R Litzow
    Mayo Clinic, Rochester, MN 55905, USA
    Br J Haematol 148:217-25. 2010
    ..We conclude that none of these three regimens were effective enough in the treatment of high-risk relapsed or refractory AML to warrant further study. This trial was registered at http://www.clinicaltrials.gov as #NCT00005962...
  89. ncbi Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma
    Jerome Landry
    Department of Radiation Oncology, Emory University School of Medicine, Atlanta, Georgia 30322, USA
    J Surg Oncol 101:587-92. 2010
    ..The trial was terminated early due to poor accrual...
  90. pmc Detection of tumor epidermal growth factor receptor pathway dependence by serum mass spectrometry in cancer patients
    Christine H Chung
    Division of Hematology Oncology, Department of Medicine, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN 37232 6307, USA
    Cancer Epidemiol Biomarkers Prev 19:358-65. 2010
    ....
  91. ncbi Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281
    Weijing Sun
    University of Pennsylvania, Philadelphia, PA 19104 4283, USA
    J Clin Oncol 23:4897-904. 2005
    ..Optimal treatments for metastatic carcinoid tumor remain undefined, and the role of chemotherapy for symptomatic patients with progressive disease is uncertain...
  92. ncbi Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188)
    Nancy E Davidson
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans St, Room 409, Baltimore, MD 21231, USA
    J Clin Oncol 23:5973-82. 2005
    ..Chemotherapy, tamoxifen, and ovarian ablation/suppression (OA/OS) are effective adjuvant approaches for premenopausal, steroid hormone receptor-positive breast cancer. The value of combined therapy has not been clearly established...
  93. ncbi A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200
    B J Giantonio
    University of Pennsylvania, Philadelphia, PA 19104, USA
    Ann Oncol 17:1399-403. 2006
    ..Following a toxicity review of other trials using IFL, subsequent patients were enrolled at reduced doses of irinotecan (100 mg/m(2)) and 5-fluorouracil (400 mg/m(2))...
  94. ncbi A randomized phase III study of radiotherapy alone or with 5-fluorouracil and mitomycin-C in patients with locally advanced adenocarcinoma of the pancreas: Eastern Cooperative Oncology Group study E8282
    Steven J Cohen
    Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111 2497
    Int J Radiat Oncol Biol Phys 62:1345-50. 2005
    ..This randomized study was undertaken to determine whether the addition of 5-fluorouracil (5-FU) and mitomycin-C (MMC) to radiation therapy improves outcome in this patient population...
  95. ncbi A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia
    Mark R Litzow
    Division of Hematology, Mayo Clinic College of Medicine, 200 First St S W, Rochester, MN 55905, USA
    Haematologica 91:1105-8. 2006
    ..One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL...
  96. ncbi The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations
    Frederick R Appelbaum
    Southwest Oncology Group Statistical Center, Seattle, WA, USA
    Br J Haematol 135:165-73. 2006
    ..021), and in patients with t(8;21) (P = 0.025). OS was superior in patients who received regimens with high-dose cytarabine, a combination of fludarabine and intermediate-dose cytarabine, or haematopoietic cell transplantation...
  97. ncbi Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group
    Michael K Gibson
    Department of Medical Oncology, Sidney Kimmell Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
    J Clin Oncol 23:3562-7. 2005
    ....
  98. ncbi Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience
    Kathleen J Yost
    Evanston Northwestern Healthcare Research Institute, USA
    Eval Health Prof 28:172-91. 2005
    ..MIDs for FACIT instruments established to date are summarized, and general guidelines that can be used to estimate MIDs for other FACIT instruments are provided. Applications of MIDs in research are illustrated...
  99. ncbi Does an oral analgesic protocol improve pain control for patients with cancer? An intergroup study coordinated by the Eastern Cooperative Oncology Group
    C S Cleeland
    The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Ann Oncol 16:972-80. 2005
    ..Cancer pain is highly prevalent and commonly undertreated. This study was designed to determine whether dissemination of a clinical protocol for pain management would improve outcomes in community oncology practices...
  100. ncbi Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group (E1993)
    Janice P Dutcher
    Albert Einstein College NY, Bronx, NY, USA
    Leuk Lymphoma 46:377-85. 2005
    ..Combination therapy with other differentiating agents may be useful in this disease...